Response to Letter to the Editor Titled "Intrathecal Pemetrexed: Another Potential Treatment Modality for TKI-Failed Leptomeningeal Metastases?"

Affiliations

¹ Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
² Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. Electronic address: xintao1234@263.net.

Free article

Comment

Chengjuan Fan et al. J Thorac Oncol. 2021 Oct.

Free article

. 2021 Oct;16(10):e85.

doi: 10.1016/j.jtho.2021.08.007.

¹ Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
² Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. Electronic address: xintao1234@263.net.

No abstract available

Comment on

Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).
Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T. Fan C, et al. J Thorac Oncol. 2021 Aug;16(8):1359-1368. doi: 10.1016/j.jtho.2021.04.018. Epub 2021 May 11. J Thorac Oncol. 2021. PMID: 33989780 Clinical Trial.
Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases?
Zheng MM, Li YS, Sun H, Chen HJ, Wu YL. Zheng MM, et al. J Thorac Oncol. 2021 Oct;16(10):e82-e84. doi: 10.1016/j.jtho.2021.06.034. J Thorac Oncol. 2021. PMID: 34561041 No abstract available.